PDCD1 and hepatocellular carcinoma: The efficacy of the anti-CTLA-4/anti-PD-1 combination ipilimumab and nivolumab after the failure of a prior PD-1/PD-L1 inhibitor-based treatment in patients with advanced HCC has not been reported yet.